Scholarly Peer Review Proteomics Journals
Proteomics is a rapidly growing field of
molecular biology that is concerned with the systematic, high-throughput approach to protein expression analysis of a cell or an organism. Typical results of
proteomics studies are inventories of the
protein content of differentially expressed proteins across multiple conditions. The cell responds to internal and external changes by regulating the activity and level of its proteins; therefore changes in the proteome (a collection of all the proteins coded in our genes) provide a snapshot of the cell in action. Proteomics enables the understanding the structure, function and interactions of the entire
protein content in a specific organism. The term “protein” was initially introduced in 1938 by the Swedish chemist Jöns Jakob Berzelius, an accomplished experimenter in the field of electrochemistry. He wanted to describe a particular class of
macromolecules that are plentiful in living organisms and made up of linear chains of amino acids. The terms “proteome” and “proteomics” were coined in the early 1990s by Marc Wilkins, a student at Australia's Macquarie University, in order to mirror the terms “genomics” and “genome”, which represent the entire collection of genes in an organism. In many ways, proteomics runs parallel to genomics. The starting point for
genomics is a
gene in order to make inferences about its products (i.e. proteins), whereas proteomics begins with the functionally modified protein and works back to the
gene responsible for its production.
High Impact List of Articles
-
Updating the clinical evidence on belimumab role modulating B-cell response and treatment of systemic lupus erythematosus
Ignasi Rodriguez-Pinto, Gerard Espinosa1 & Ricard Cervera
Drug Evaluation: Clinical Investigation
-
Updating the clinical evidence on belimumab role modulating B-cell response and treatment of systemic lupus erythematosus
Ignasi Rodriguez-Pinto, Gerard Espinosa1 & Ricard Cervera
Drug Evaluation: Clinical Investigation
-
Updating the clinical evidence on belimumab role modulating B-cell response and treatment of systemic lupus erythematosus
Ignasi Rodriguez-Pinto, Gerard Espinosa1 & Ricard Cervera
Drug Evaluation: Clinical Investigation
-
Updating the clinical evidence on belimumab role modulating B-cell response and treatment of systemic lupus erythematosus
Ignasi Rodriguez-Pinto, Gerard Espinosa1 & Ricard Cervera
Drug Evaluation: Clinical Investigation
-
Updating the clinical evidence on belimumab role modulating B-cell response and treatment of systemic lupus erythematosus
Ignasi Rodriguez-Pinto, Gerard Espinosa1 & Ricard Cervera
Drug Evaluation: Clinical Investigation
-
Updating the clinical evidence on belimumab role modulating B-cell response and treatment of systemic lupus erythematosus
Ignasi Rodriguez-Pinto, Gerard Espinosa1 & Ricard Cervera
Drug Evaluation: Clinical Investigation
-
Updating the clinical evidence on belimumab role modulating B-cell response and treatment of systemic lupus erythematosus
Ignasi Rodriguez-Pinto, Gerard Espinosa1 & Ricard Cervera
Drug Evaluation: Clinical Investigation
-
Updating the clinical evidence on belimumab role modulating B-cell response and treatment of systemic lupus erythematosus
Ignasi Rodriguez-Pinto, Gerard Espinosa1 & Ricard Cervera
Drug Evaluation: Clinical Investigation
-
Co-morbidities and their underappreciated impact on the conversion of oncology trial results into routine clinical practice
Maurie Markman
Editorial: Clinical Investigation
-
Co-morbidities and their underappreciated impact on the conversion of oncology trial results into routine clinical practice
Maurie Markman
Editorial: Clinical Investigation
-
Co-morbidities and their underappreciated impact on the conversion of oncology trial results into routine clinical practice
Maurie Markman
Editorial: Clinical Investigation
-
Co-morbidities and their underappreciated impact on the conversion of oncology trial results into routine clinical practice
Maurie Markman
Editorial: Clinical Investigation
-
Co-morbidities and their underappreciated impact on the conversion of oncology trial results into routine clinical practice
Maurie Markman
Editorial: Clinical Investigation
-
Co-morbidities and their underappreciated impact on the conversion of oncology trial results into routine clinical practice
Maurie Markman
Editorial: Clinical Investigation
-
Co-morbidities and their underappreciated impact on the conversion of oncology trial results into routine clinical practice
Maurie Markman
Editorial: Clinical Investigation
-
Co-morbidities and their underappreciated impact on the conversion of oncology trial results into routine clinical practice
Maurie Markman
Editorial: Clinical Investigation
-
Ibudilast for the treatment of drug addiction and other neurological conditions
Kirk W Johnson, Kazuko Matsuda & Yuichi Iwaki
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ibudilast for the treatment of drug addiction and other neurological conditions
Kirk W Johnson, Kazuko Matsuda & Yuichi Iwaki
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ibudilast for the treatment of drug addiction and other neurological conditions
Kirk W Johnson, Kazuko Matsuda & Yuichi Iwaki
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ibudilast for the treatment of drug addiction and other neurological conditions
Kirk W Johnson, Kazuko Matsuda & Yuichi Iwaki
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ibudilast for the treatment of drug addiction and other neurological conditions
Kirk W Johnson, Kazuko Matsuda & Yuichi Iwaki
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ibudilast for the treatment of drug addiction and other neurological conditions
Kirk W Johnson, Kazuko Matsuda & Yuichi Iwaki
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ibudilast for the treatment of drug addiction and other neurological conditions
Kirk W Johnson, Kazuko Matsuda & Yuichi Iwaki
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ibudilast for the treatment of drug addiction and other neurological conditions
Kirk W Johnson, Kazuko Matsuda & Yuichi Iwaki
Review: Clinical Trail Outcomes: Clinical Investigation
-
Interview with Professor Morris Brown
Morris Brown
Interview: Clinical Investigation
-
Interview with Professor Morris Brown
Morris Brown
Interview: Clinical Investigation
-
Interview with Professor Morris Brown
Morris Brown
Interview: Clinical Investigation
-
Interview with Professor Morris Brown
Morris Brown
Interview: Clinical Investigation
-
Interview with Professor Morris Brown
Morris Brown
Interview: Clinical Investigation
-
Interview with Professor Morris Brown
Morris Brown
Interview: Clinical Investigation
-
Interview with Professor Morris Brown
Morris Brown
Interview: Clinical Investigation
-
Interview with Professor Morris Brown
Morris Brown
Interview: Clinical Investigation
-
What the new US FDA guidance in assessing suicidal ideation and behavior in clinical trials means for trial design
David W Morris
Editorial: Clinical Investigation
-
What the new US FDA guidance in assessing suicidal ideation and behavior in clinical trials means for trial design
David W Morris
Editorial: Clinical Investigation
-
What the new US FDA guidance in assessing suicidal ideation and behavior in clinical trials means for trial design
David W Morris
Editorial: Clinical Investigation
-
What the new US FDA guidance in assessing suicidal ideation and behavior in clinical trials means for trial design
David W Morris
Editorial: Clinical Investigation
-
What the new US FDA guidance in assessing suicidal ideation and behavior in clinical trials means for trial design
David W Morris
Editorial: Clinical Investigation
-
What the new US FDA guidance in assessing suicidal ideation and behavior in clinical trials means for trial design
David W Morris
Editorial: Clinical Investigation
-
What the new US FDA guidance in assessing suicidal ideation and behavior in clinical trials means for trial design
David W Morris
Editorial: Clinical Investigation
-
What the new US FDA guidance in assessing suicidal ideation and behavior in clinical trials means for trial design
David W Morris
Editorial: Clinical Investigation
-
Translational biomarker in early oncology clinical development: decision case study for MEK inhibitors in healthy volunteer studies
Lucy Lee
Special Report: Clinical Investigation
-
Translational biomarker in early oncology clinical development: decision case study for MEK inhibitors in healthy volunteer studies
Lucy Lee
Special Report: Clinical Investigation
-
Translational biomarker in early oncology clinical development: decision case study for MEK inhibitors in healthy volunteer studies
Lucy Lee
Special Report: Clinical Investigation
-
Translational biomarker in early oncology clinical development: decision case study for MEK inhibitors in healthy volunteer studies
Lucy Lee
Special Report: Clinical Investigation
-
Translational biomarker in early oncology clinical development: decision case study for MEK inhibitors in healthy volunteer studies
Lucy Lee
Special Report: Clinical Investigation
-
Translational biomarker in early oncology clinical development: decision case study for MEK inhibitors in healthy volunteer studies
Lucy Lee
Special Report: Clinical Investigation
-
Translational biomarker in early oncology clinical development: decision case study for MEK inhibitors in healthy volunteer studies
Lucy Lee
Special Report: Clinical Investigation
-
Translational biomarker in early oncology clinical development: decision case study for MEK inhibitors in healthy volunteer studies
Lucy Lee
Special Report: Clinical Investigation
Relevant Topics in Clinical